Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic
Concept/Terms
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Compounds, 3-Ring Heterocyclic
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in Harvard Catalyst Profiles by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 3 | 4 |
| 2016 | 2 | 3 | 5 |
| 2017 | 4 | 5 | 9 |
| 2018 | 13 | 4 | 17 |
| 2019 | 8 | 5 | 13 |
| 2020 | 9 | 3 | 12 |
| 2021 | 6 | 9 | 15 |
| 2022 | 1 | 6 | 7 |
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations. Expert Rev Clin Immunol. 2023 01; 19(1):19-35.
-
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort. Clin Infect Dis. 2022 09 10; 75(4):715-718.
-
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med. 2022 09 01; 387(9):799-809.
-
Upadacitinib for ulcerative colitis. Lancet. 2022 06 04; 399(10341):2077-2078.
-
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV. 2022 05; 9(5):e332-e340.
-
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. J Acquir Immune Defic Syndr. 2022 05 01; 90(1):27-32.
-
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. AIDS. 2022 Sep 01; 36(11):1511-1520.
-
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021 12 15; 35(Suppl 2):S127-S135.
-
Dolutegravir and rat whole embryo culture. Birth Defects Res. 2022 01 01; 114(1):23-24.
-
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021 10; 7(3).